EHA 2025 | The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification
In this video, Fabio Guolo, MD, University of Genoa, Genoa, Italy, briefly discusses the efficacy of CPX-351 in secondary acute myeloid leukemia (AML), highlighting that the therapy remains effective when using the 2022 World Health Organization (WHO) classification of secondary AML. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We know that CPX-351 has a great efficacy in secondary AML. Following the results of Phase III trials by Lancet, we know that it is more effective than conventional chemotherapy. We know that this is at least when we define secondary AML according to the previous WHO classification of 2016, which was the classification that was used in the Phase III trial. We still do not know if we apply the newer WHO classification, which implies a genetic-driven classification of secondary AML, if this still holds true...
We know that CPX-351 has a great efficacy in secondary AML. Following the results of Phase III trials by Lancet, we know that it is more effective than conventional chemotherapy. We know that this is at least when we define secondary AML according to the previous WHO classification of 2016, which was the classification that was used in the Phase III trial. We still do not know if we apply the newer WHO classification, which implies a genetic-driven classification of secondary AML, if this still holds true. So in our experience, we tried to reclassify secondary AML according to the new classification, and we saw that CPX351 is effective even in the secondary AML defined molecularly. This is in line with the British trial results when patients who had myelodysplasia-related gene aberration did better with CPX than conventional chemo. So that’s relevant information.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
